Innovative Therapeutic Modalities and Translational Platforms

• 283 · PDF Severe acidity in human tumors for pH-activatable cytokine therapy Qiang Feng, Jun Chen, William Hartnett, Raymundo Pantoja, Gang Huang, Isaac Chan, Baran Sumer, Jinming Gao
• 284 · PDF From undruggable to actionable: Transcriptomic discovery of small-molecule modulators of oncogenic transcription factors Arianna Sabò, QUANTRO's Team
• 285 · PDF NEBNext UltraShear ® Long Read: Enzymatic DNA fragmentation for long read sequencing of clinically relevant samples Keerthana Krishnan, Brittany S. Sexton, Matt Angel, Karen McKay, Jonathan Sanford, Ruby Moulton, Louise Williams, Bradley W. Langhorst, Pingfang Liu, V.K. Chaithanya Ponnaluri
• 286 · PDF New approach methodologies for risk assessment and functional evaluation of immuno-oncology drug candidates Christoph Schifflers, Martijn Vlaming, Sofie Pattyn
• 287 · PDF Chemically ligated proteins enable quantitative ELISAs for p53 post-translational modifications Thomas Bailey
• 288 · PDF Two-color bioluminescence analyses pairing NanoLuc® and red-shifted NanoPrism™ luciferases​ Juliano Alves, Karilyn Porter, Mike Killoran, Robin Hurst, Mark Klein, Debayan De Bakshi, Rahele Esmatpour, James J. Cali, Thomas Machleidt, Rachel F. Ohana, Hicham Zegzouti
• 289 · PDF Tracking APOBEC3A to overcome drug resistance in lung cancer Maria Vittoria Di Marco, Christopher Eggers, Aaron N. Hata
• 290 · PDF Scientific justification for setting up an appropriate specification of residual solvent based on ICH guideline Zhanxiang Sun, Jianqiang Li, Lynn Wang, Xudong Wei
• 291 · PDF Dual PHD2-HDAC inhibitor 31c prevents cisplatin-bevacizumab nephrotoxicity and preserves antitumor efficacy in cervical cancer Xi Chen, Dongyu Han, Xiaohua Kong, Wenfeng Gou, Yang Song, Huiqiang Wei, Yiliang Li, Yong Qin
• 292 AOH1996, a cancer-associated PCNA inhibitor, restores platinum sensitivity in urothelial carcinoma: In vitro and in vivo study Kuan-Lin Kuo, Kuo-How Huang, Yi Ju (Ellen) Kao, Chen-Hsun Hsu
• 293 · PDF Anti-cancer drug usage analysis among Korean patients with colorectal cancer Yu Jin Lim, Jeongseon Kim
• 294 · PDF Comparative biochemical kinase activity analysis identifies lirafugratinib as a highly selective FGFR2 inhibitor Alison M. Schram, Grace Lee, Tracey Wei, Seong Jang, Kristin Ryan
• 295 · PDF Antitumor effect of a new pyruvate kinase M2 (PKM2) inhibitor Acyclovir in experimental esophageal adenocarcinoma Md Sazzad Hassan, Mallory Turner, Elizabeth Heffernan, Katherine Millett, Oliver O’Reilly, Niranjan Awasthi, Usama Usama, Aktar Ali, Urs von Holzen
• 296 · PDF Evaluation of ingenane diterpenoids for BL2 triple-negative breast cancer Pamela R. Duarte, April L. Risinger
• 297 Cymirafen: A protein-drug conjugate that delivers very intense short pulses of MMAE on a weekly schedule Maria Carmen Mulero Roig, Sukshala A. Jadhav, Willie Pi, Stephen B. Howell
• 298 An engineered human myeloid cell line with a UBA1 mutation frequently detected in VEXAS syndrome is sensitive to the proteasome inhibitor bortezomib Hina Yazawa, Youhei Sasaki, Norihiko Kawamata
• 299 · PDF From factory to patient: In vivo ‑expressed biologics as a new paradigm for immunotherapy manufacturing Henry Leonard, Dan Rocca, Philipp Meyer, Ina Rohleff, Eva Oswald, Sarah L. Martin, Matthew Benson, Namrata Jayanth, Christian Cobaugh, Michael Shaw, Julia Schueler, Gemma Moiset, Roxana Redis, Louise Brackenbury, Justin Bryans
• 300 · PDF Mapping cellular fate: From metabolic dynamics to DNA damage responses Lorena Sueiro-Ballesteros, Henry Leonard, Dan Rocca, Lauren Schewitz-Bowers, Louise Brackenbury
• 301 · PDF Population pharmacokinetics of nab-paclitaxel following administration of a nano-immunoconjugate with bevacizumab Mohd Beshr Chama, Matthew Stephen Block, Vera J. Suman, Joel M. Reid
• 302 Evaluating the influence of cholesterol content on the cellular uptake and formulation activity of nanoliposomal formulations against uveal melanoma Shrey Mehulkumar Patel, Francielle Mourisso, Bilal Habibeh, Anna Kleckerova, Robert B. Campbell
• 303 · PDF Turning tumors into therapeutic drug factories: Efficacy across oncology indications Moataz Reda, Blaine McCarthy, Sushil Lathwal, Evan Bishop, Priyanka Balasubrahmanyam, Robby Chandra, Nikki Kimura, Xiao Wu, Kim Tran, Jesse Simons, Ajda Rojc, Jayalakshmi Ramani, Dang Dang, David Rosen, Badri Ananthanarayanan, Nadege Morisot, David Suhy
• 304 A phase 1 study of intratumoral ultra-high concentration nitric oxide (UNO) gas injection in cutaneous and subcutaneous solid tumor metastases Amichay Meirovitz, Steve Lisi, Kim Sheva, David Greenberg, John Jett
• 305 Non-melanoma skin cancer treated with electrochemotherapy: Clinical outcomes and tolerability Felipe Horacio Maglietti, Raquel Lertora, Nazarena S. Martinez, Alexandre Da Rosa Silva, Marina Ribeiro Damasceno Silva, Sebastian D. Michinski
• 306 Integrative computational and functional genomic approach reveals UBE2Z-UBR2-Ecadherinaxis as a beta-catenin-specific vulnerability in colorectal cancer Chunhua Wan, Hugh Gao, Claire Sun, Ron Firestein
• 307 Triple-negative breast cancer growth and metastasis suppression by CCN5 is mediated by Merlin/NF2 and Orai-1 molecular signatures Inamul Haque, Gargi Maity, Jamie L. Porter, Snigdha Banerjee, Sushanta K. Banerjee
• 308 Melatonin activity in uterine leiomyoma and leiomyosarcoma cell lines: A preliminary study of its inhibitory potential in mesenchymal tumors Tatielly T. Miranda, Edmund C. Baracat, Roseli S. Soares, Katia C. Carvalho
• 309 · PDF Oncogenic cooperation of MUC13 and NDRG1 signaling in liver cancer Shabnam Malik, Mohammed Sikander, Daniel Zubieta, Mirza Sarwar Baig, Iris Enriquez, Murali M. Yallapu, Subhash C. Chauhan
• 310 Translational development of NEU-002: Engineered therapeutic elastases demonstrate systemic anti-tumor activity via intraperitoneal and intravenous administration Maria Fumagalli, Chang Cui, Ravindra Gujar, Nicole Martinez, Peter Haberz, Court Turner, Lev Becker
• 311 Integrated strategies for producing functional recombinant proteins to advance autoimmune disease therapeutics Wenlin Ren, Siwen Wang, An Ouyang, Spencer Chiang, Yu Sun
• 312 Postbiotic based on sequential fermentation of L.paracasei NPB01 and L.rhamnosus GG exerts antitumor activities against breast cancer Roberto Berni Canani, Chiara Luongo, Laura Pisapia, Franca Oglio, Roberta Di Santillo, Alessia Gaeta, Chiara Scocco, Marco Michelini, Vittoria Mauriello, Alessia Cadavere, Camilla Messuri, Saranya Chumsri, Dawn Mussallem

在完整检索应用中浏览本分会场 →